Delving into the Latest Updates on Interprotein Corp. with Synapse

概览

疾病领域	数量

免疫系统疾病	8
肿瘤	7
血液及淋巴系统疾病	1
感染	1

排名前五的药物类型	数量

小分子化药	9
重组多肽	5
化学药	2

排名前五的靶点	数量

TNF-α(肿瘤坏死因子α)	7
TIM3(甲型肝炎病毒细胞受体2)	5
VEGF(血管内皮生长因子)	1
3C-L Pro(病毒3C-Like蛋白酶)	1
IgE(免疫球蛋白E)	1

关联

18

项与 Interprotein Corp. 相关的药物

S-0871

靶点

TNF-α

作用机制

TNF-α抑制剂

在研机构

Interprotein Corp.

原研机构

Interprotein Corp.

在研适应症

免疫系统疾病

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

IT-201

靶点

TIM3

作用机制

TIM3抑制剂

在研机构

Interprotein Corp.

原研机构

Interprotein Corp.

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

IT-205

靶点

TIM3

作用机制

TIM3抑制剂

在研机构

Interprotein Corp.

原研机构

Interprotein Corp.

在研适应症

肿瘤

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Interprotein Corp. 相关的临床结果

登录后查看更多信息

0 项与 Interprotein Corp. 相关的专利（医药）

登录后查看更多信息

12

项与 Interprotein Corp. 相关的文献（医药）

2024-03-03·Natural Product Research

Antiviral activity of curcumin and its analogs selected by an artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells

Article

作者: Matsuzaki, Takao ; Ikeda, Ken ; Tanaka, Takeshi ; Hosoda, Masato ; Yasugi, Mayo ; Shiroma, Tamotsu ; Komatsu, Hirotsugu ; Ye, Zhengmao ; Teshima, Koji ; Muroya, Ayumu

Curcumin has been reported to exert its anti-SARS-CoV-2 activity by inhibiting the binding of spike receptor-binding domain (RBD) to angiotensin-converting enzyme-2 (ACE2). To identify more potent compounds, we evaluated the antiviral activities of curcumin and its analogs in SARS-CoV-2-infected cells. An artificial intelligence-supported activity prediction system was used to select the compounds, and 116 of the 334 curcumin analogs were proposed to have spike RBD-ACE2 binding inhibitory activity. These compounds were narrowed down to eight compounds for confirmatory studies. Six out of the eight compounds showed antiviral activity with EC₅₀ values of less than 30 µM and binding inhibitory activity with IC₂₀ values of less than 30 µM. Structure-activity relationship analyses revealed that the double bonds in the carbon chain connecting the two phenolic groups were essential for both activities. X-ray co-crystallography studies are needed to clarify the true binding pose and design more potent derivatives.

2023-03-24·Journal of Biomolecular Structure and Dynamics

Identification of SARS-CoV-2 main protease inhibitors from FDA-approved drugs by artificial intelligence-supported activity prediction system

Article

作者: Ye, Zhengmao ; Hosoda, Masato ; Ikeda, Ken ; Yasugi, Mayo ; Komatsu, Hirotsugu ; Tanaka, Takeshi ; Matsuzaki, Takao

Although a certain level of efficacy and safety of several vaccine products against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) have been established, unmet medical needs for orally active small molecule therapeutic drugs are still very high. As a key drug target molecule, SARS-CoV-2 main protease (M^pro) is focused and large number of in-silico screenings, a part of which were supported by artificial intelligence (AI), have been conducted to identify M^pro inhibitors both through drug repurposing and drug discovery approaches. In the many drug-repurposing studies, docking simulation-based technologies have been mainly employed and contributed to the identification of several M^pro binders. On the other hand, because AI-guided INTerprotein's Engine for New Drug Design (AI-guided INTENDD), an AI-supported activity prediction system for small molecules, enables to propose the potential binders by proprietary AI scores but not docking scores, it was expected to identify novel potential M^pro binders from FDA-approved drugs. As a result, we selected 20 potential M^pro binders using AI-guided INTENDD, of which 13 drugs showed M^pro-binding signal by surface plasmon resonance (SPR) method. Six (6) compounds among the 13 positive drugs were identified for the first time by the present study. Furthermore, it was verified that vorapaxar bound to M^pro with a K_d value of 27 µM by SPR method and inhibited virus replication in SARS-CoV-2 infected cells with an EC₅₀ value of 11 µM. Communicated by Ramaswamy H. Sarma.

2022-01-01·Proceedings for Annual Meeting of The Japanese Pharmacological Society

Antiviral activity of curcumin and its analogs selected by artificial intelligence-supported activity prediction system in SARS-CoV-2-infected VeroE6 cells

作者: Teshima, Koji ; Ye, Zhengmao ; Hosoda, Masato ; Ikeda, Ken ; Komatsu, Hirotsugu ; Tanaka, Takeshi ; Yasugi, Mayo ; Matsuzaki, Takao ; Shiroma, Tamotsu

100 项与 Interprotein Corp. 相关的药物交易

登录后查看更多信息

100 项与 Interprotein Corp. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2024年11月20日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

16

2

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

S-0999 ( TNF-α )	免疫系统疾病更多	临床前
IT-203 ( TIM3 )	肿瘤更多	临床前
S-0765 ( TNF-α )	免疫系统疾病更多	临床前
VEGF 抑制剂(Interprotein) ( VEGF )	实体瘤更多	临床前
IPC-003 ( Tubulin )	血液疾病更多	临床前